Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Geron, retaining the price target of $3.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Faisal Khurshid has given his Buy rating due to a combination of factors that indicate positive momentum for Geron. The management’s commentary during the 2Q25 earnings call highlighted a growing demand for Rytelo, particularly in the early-line treatment of lower-risk myelodysplastic syndromes (LR-MDS). This growth is supported by the company’s renewed commercial strategies and an expanded field team, which are expected to further enhance Rytelo’s market presence in the latter half of 2025.
Additionally, the appointment of a new CEO with relevant experience in hematology is seen as a strategic move to address previous commercial execution challenges. The revenue figures for the quarter exceeded consensus expectations, with a notable increase attributed to new patient starts. These developments, along with management’s optimism and the increase in the number of accounts ordering Rytelo, reinforce the potential for sustained growth and justify the Buy rating.
Khurshid covers the Healthcare sector, focusing on stocks such as aTyr Pharma, Spyre Therapeutics, and Rhythm Pharmaceuticals. According to TipRanks, Khurshid has an average return of 26.9% and a 59.18% success rate on recommended stocks.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $4.00 price target.